Ocuphire Pharma Inc (R3X1.MU)
| Previous Close | 1.0960 |
| Open | 1.0960 |
| Bid | 1.0740 x N/A |
| Ask | 1.1040 x N/A |
| Day's Range | 1.0960 - 1.0960 |
| 52 Week Range | 1.0620 - 2.9650 |
| Volume | |
| Avg. Volume | 12 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireThe RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company. The companies have combined under the name of Opus Genetics to create a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of inherited retinal diseases (IRDs). The com
TipRanksOcuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics
Ocuphire Pharma ( (OCUP) ) just unveiled an update. Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, forming a leading biotech company focused on gene therapies for inherited retinal diseases (IRDs). This strategic move will see the company renamed Opus Genetics, Inc. and trading under the ticker ‘IRD.’ With promising early data, the merger brings together a strong leadership team to advance groundbreaking therapies, while extending the cash runway into 2026. Investors can expe
